CoChat

The calm after the cytokine storm: lessons from the TGN1412 trial

Open access
St. Clair, E. William · 2008 · Journal of Clinical Investigation

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index; 16 of the 32 sources its claims cite were checked for support.

Abstract

In March 2006, a phase I study of the superagonistic anti-CD28 antibody TGN1412 caused a massive cytokine storm and multiorgan failure in six healthy human volunteers. Such a profound impact on the immune system was not predicted by preclinical animal studies. In a study from this issue of the JCI, Müller et al. treated rats with the superagonistic anti-CD28 antibody JJ316 and found that it rapidly induced a marked T cell lymphopenia by trapping T cells in the spleen and lymph nodes (see the related article beginning on page 1405). This dramatic redistribution of T cells simulated the profound T cell lymphopenia observed in human recipients of TGN1412. In contrast, JJ316 treatment in the rats did not reproduce the massive cytokine storm observed following TGN1412 administration to the human volunteers. These results point to similarities as well as differences between rodents and humans in the immunological effects of superagonistic anti-CD28 antibody treatment and raise further questions about how best to design preclinical studies that can better predict the risks of novel immunotherapeutics in humans.

Overview

CoChat Summary

TL;DR

This commentary reviews the 2006 Northwick Park TGN1412 disaster, in which a superagonistic anti-CD28 antibody caused a massive cytokine storm and multiorgan failure in six healthy volunteers, and asks why preclinical animal studies failed to predict it. It highlights Müller et al.'s accompanying rat study showing that the rat-equivalent antibody JJ316 reproduces the T cell lymphopenia but not the cytokine storm, and endorses the Expert Scientific Group's 22 recommendations for first-in-human trials.

Key findings

All six volunteers receiving TGN1412 developed a systemic inflammatory response within 90 minutes, with profound lymphopenia nadir at 24 hours, multiorgan failure lasting 1–2 weeks, and gradual improvement over 2–4 weeks; the batch was later found free of endotoxin or manufacturing error, implicating CD28 ligation itself. The starting dose of 0.1 mg/kg was a 500th of the no-observed-adverse-effect level (50 mg/kg) in nonhuman primates, where only moderate IL-2, IL-5, and IL-6 rises occurred with no significant IL-4, IFNγ, or TNFα changes. Müller et al. found JJ316 in rats caused rapid redistribution of all CD4+ T cells to spleen and lymph nodes via reduced motility, increased adhesion to fibronectin, and downregulated EDG-1, plus two waves of T cell activation — but only mildly elevated TNFα and IFNγ, orders of magnitude below human levels. Stebbings et al. showed TGN1412 induced large TNFα, IL-6, and IL-8 release from human PBMCs (air-dried, 1.0 and 10.0 μg/well) and in PBMC–endothelial coculture, but not from cynomolgus PBMCs.

Methods

Narrative commentary/retrospective review of the TGN1412 phase I trial, the TeGenero investigator brochure, the MHRA evaluation, and the ESG report, synthesizing these with the accompanying Müller et al. rat study and other published preclinical work (Stebbings et al., Legrand et al., Nguyen et al.). No primary data collection; the paper's own analysis is interpretive.

Limitations

The paper states it will probably never be known whether a lower starting dose would have attenuated the adverse events. Evident from the text: this is a commentary rather than an original study, so its claims rest on secondary sources; the rat model (JJ316) only partially mimics human responses, and the human CD28 sequence differs from macaque by four amino acids including a G68E substitution, limiting cross-species extrapolation.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1172/jci35382

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

16 Valid · 3 Not valid · 14 Not checked · 17 Own results and interpretations

14 more claims · 1 with their cited sources checked

Create a free account to see all 50 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 11
  • It may state two separate claims as one. 13
  • Not yet classified. 9

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 11 references

Research works printed but not linked: 2

  1. Rodríguez-Palmero, 2006, J. Rheumatol., 33, 110
  2. TeGenero AG Investigator’s Brochure. TGN1412 humanized agonistic anti-CD28 monoclonal antibody. Edition 1.1. http://www.circare.org/foia5/tgn1412investigatorbrochure.pdf.

Cited by

See all 79

Metadata

Authors
St. Clair, E. W.
Venue
Journal of Clinical Investigation
Published
2008-04-01
Volume
118
Issue
4
Pages
1344-1347
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2066070407
Cited by
79
References
11
Citations by year
2026: 2 · 2025: 3 · 2024: 3 · 2023: 1 · 2022: 3 · 2021: 2 · 2020: 2 · 2019: 5 · 2018: 7 · 2017: 5 · 2016: 4 · 2015: 3 · 2014: 7 · 2013: 3 · 2012: 6
FWCI
2.70
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
TGN1412, cytokine storm, T-cell lymphopenia, T cell redistribution, preclinical animal models, multiple organ failure
MeSH terms
Animals, Antibodies, Monoclonal, Clinical Trials as Topic, Humans, Lymphopenia, Drug Design, Cytokines, CD28 Antigens, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The calm after the cytokine storm: lessons from the TGN1412 trial. https://app.cochat.ai/papers/10.1172/jci35382
The paper
St. Clair, E. W. (2008). The calm after the cytokine storm: lessons from the TGN1412 trial. Journal of Clinical Investigation. https://doi.org/10.1172/jci35382

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.